Celularity

Celularity Days Payable Outstanding

The Days Payable Outstanding (DPO) of Celularity (CELU) as of Oct 16, 2026 is 1,515.88. In the previous year, Days Payable Outstanding (DPO) was 567.29 — a change of 167.22% (higher).

Days Payable Outstanding

1,515.88

YoY

167.22%

Last updated:

Days Payable Outstanding (DPO) of Celularity is 2025 1,515.88 . Days Payable Outstanding (DPO) of Celularity was 2024 567.29 . It decreases by 167.22% higher compared to the previous year.

The Celularity Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
293.34 USD
Jan 1, 2019
1.09 USD
Jan 1, 2020
398.89 USD
Jan 1, 2021
352.30 USD
Jan 1, 2022
107.84 USD
Jan 1, 2023
771.45 USD
Jan 1, 2024
567.29 USD
Jan 1, 2025
1,515.88 USD
The Celularity Days Payable Outstanding history
YEARDays Payable OutstandingYoY
1,515.88+167.22%
567.29-26.47%
771.45+615.38%
107.84-69.39%
352.30-11.68%
398.89+36,500.46%
1.09-99.63%
293.34—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celularity Stock analysis

What does Celularity do? Celularity Inc, listed on the stock market with ticker CELU and ISIN US1511902041, is a biotechnology company headquartered in Florham Park, New Jersey, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Celularity has 225 employees and completed its initial public offering (IPO) on May 23, 2019. The company focuses on developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune disorders, and infectious diseases. Its research and development efforts include various therapy product candidates such as T cells engineered with a chimeric antigen receptor (CAR), natural killer cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target a range of conditions including cancer, infectious diseases, and degenerative diseases. Celularity's product pipeline features several programs, including CYCART-19, which is a placental-derived CAR-T cell therapy targeting B-cell malignancies, and pEXO-001, among others. The company's operations are structured around three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Celularity's website is https://celularity.com/. Celularity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celularity stock

Days Payable Outstanding (DPO) of Celularity is 1,515.88 in 2025.

Days Payable Outstanding (DPO) of Celularity changed from 567.29 to 1,515.88, representing a 167.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Celularity since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Celularity with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Celularity

All Key Metrics — Celularity